A nephrologist argues that advancing kidney care in the US requires tailored guidelines addressing ethnic diversity & fragmented healthcare.

Adding pembrolizumab to docetaxel did not significantly improve outcomes in previously treated patients with mCRPC.

Even among patients with prostate cancer liver metastasis who have a poor prognosis, elevated ctDNA fraction and tumor suppressor gene loss differentiate survival.